In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C for Kalypsys results in $100mm

Executive Summary

Kalypsys, which has a pipeline of clinical compounds for obesity, neuropathic pain, and cancer, grossed $100mm in its Series C financing. Existing shareholder Tavistock Life Sciences, which invested $89mm, was joined by other returning backers Sprout Group, CMEA Ventures, and KT Venture Group.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies